Aspira Women’s Health (AWH) - 2024 Q3 - Quarterly Results

FORM 8-K Filing Details This section outlines the basic identification and purpose of the Form 8-K filing for Aspira Women's Health Inc General Information This section provides the basic identification details for the Form 8-K filing, including the registrant's name, jurisdiction, commission file number, and principal executive offices - Registrant: Aspira Women's Health Inc.[1] - Date of Report (Date of earliest event reported): November 14, 2024[1] Purpose of Filing The Form 8-K is filed to report selected financial results for the three and nine months ended September 30, 2024, which were announced via a press release - The filing is pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934[1] - The registrant is not an emerging growth company[2] Item 2.02 Results of Operations and Financial Condition This item reports the selected financial results for Aspira Women's Health Inc. for the three and nine months ended September 30, 2024 Reporting of Selected Financial Results Aspira Women's Health Inc. issued a press release on November 14, 2024, to report selected financial results for the three and nine months ended September 30, 2024. This press release is attached as Exhibit 99.1, and the information is furnished, not filed, under the Exchange Act - On November 14, 2024, Aspira Women's Health Inc. issued a press release reporting selected financial results[2] - The reported financial results are for the three and nine months ended September 30, 2024[2] - The press release is attached as Exhibit 99.1 and is furnished, not deemed 'filed,' for purposes of Section 18 of the Securities Exchange Act of 1934[2][3] Item 9.01 Financial Statements and Exhibits This item lists the exhibits accompanying the Form 8-K, including the press release and interactive data file List of Exhibits This section lists the documents furnished as exhibits to the Form 8-K, including the press release detailing financial results and the interactive data file for the cover page Exhibits to Form 8-K | Exhibit No. | Description | | :---------- | :--------------------------------------------------------------------------------------------------------------------------------------- | | 99.1 | Press Release issued by Aspira Women's Health Inc. on November 14, 2024 | | 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) | Signatures This section confirms the authorized signatory for the Form 8-K filing Authorized Signatory The report was duly signed on behalf of Aspira Women's Health Inc. by its Interim Chief Financial Officer, John Kallassy, on November 14, 2024 - The report was signed by John Kallassy, Interim Chief Financial Officer[5] - Date of signature: November 14, 2024[5]